Catalog No.
Product Name
Application
Product Information
Citations
-
Tau Fibril Binding Agent
BF-170 is a selective tau fibril binding agent that targets tau protein aggregates, exhibiting an EC50 of 221 nM. It demonstrates effective blood-brain barrier permeability, with brain tissue concentrations reaching 9.1% ID/g within 2 minutes post intravenous administration in mice. BF-170 serves as a valuable tool for imaging tau pathology associated with Alzheimer's disease and is instrumental in early-stage AD research, offering potential for studies focused on tau-related neurodegenerative disorders. -
Tau fragment
Tau Peptide (244-274) targets the Repeat 1 domain of the tau protein, a key player in neurodegenerative diseases such as Alzheimer's. This peptide fragment is commonly utilized in research to study tau pathology, including phosphorylation and aggregation processes associated with tau-mediated toxicity. Its role in modulating tau interactions makes it a valuable tool for investigating tau-related mechanisms in various cellular models. -
Tau Ligand
Aberrant tau ligand 2 (Compound 4-12) selectively targets the tau protein, serving as a crucial ligand in research on tau pathology. This compound plays an essential role in the development of PROTAC degraders, specifically for the synthesis of C004019, facilitating studies on tau-related neurodegenerative diseases. Its application in the exploration of targeted protein degradation highlights its significance in advancing therapeutic strategies. -
TTBK1 Inhibitor
TTBK1-IN-4 is a potent inhibitor of TTBK1, exhibiting a biochemical IC₅₀ of 2.3 nM and a cellular IC₅₀ of 42 nM. This compound serves as a valuable tool for investigating the role of TTBK1 in neurodegenerative diseases, particularly Alzheimer's disease. Researchers can utilize TTBK1-IN-4 to explore its potential therapeutic implications and the underlying mechanisms associated with TTBK1 activity. -
Tau Disaggregator
D-TLKIVWC functions as a tau fibril disaggregator, effectively reducing tau aggregation through the disruption of intermolecular hydrogen bonds via a stress-release mechanism. Its low immunogenicity and anti-degradation properties make it a valuable tool in research. D-TLKIVWC is particularly relevant for studies surrounding amyloid diseases, including Alzheimer's disease, facilitating insights into tau-related pathologies. -
Norepinephrine metabolite
Dopegal is a metabolite of norepinephrine that primarily targets asparagine endopeptidase. It is known to induce pathological tau aggregation in the locus coeruleus, making it an important tool in studying neurodegenerative diseases. Research applications include the investigation of tau pathology and the mechanisms underlying neurodegeneration associated with norepinephrine dysregulation. -
Tau fragment
Tau Peptide (245-274) (Repeat 1 Domain) is a specific fragment of the Tau protein that serves as a crucial target in neurodegenerative research. This peptide is involved in the formation of neurofibrillary tangles, which are characteristic of Alzheimer's disease and other tauopathies. It can be used in studies investigating tau aggregation and toxicity, as well as in the development of therapeutics aimed at modulating tau pathology. -
Tau fragment
Tau Peptide (294-305) (human) is a biologically active fragment of the Tau protein that plays a critical role in neurodegenerative diseases, particularly in Alzheimer’s disease. This peptide is instrumental in studying tau pathology, including tau aggregation and neurofibrillary tangles. It serves as an important tool for researchers investigating the mechanisms of tau-related neurodegeneration and developing potential therapeutic approaches. -
Tau fragment
Tau Peptide (45-73) (Exon 2/Insert 1 Domain) is a fragment of the Tau protein that plays a crucial role in stabilizing microtubules. This peptide is often used in research studies focusing on neurodegenerative diseases, particularly Alzheimer's disease, where Tau pathology is implicated. It serves as a valuable tool for investigating Tau aggregation, cellular interactions, and the effects of post-translational modifications on Tau function. -
Tau-aggregation Inhibitor
Tau-aggregation-IN-5 is a potent inhibitor of Tau aggregation with an EC50 of 0.31 μM, targeting P4HB covalently. This compound induces mild endoplasmic reticulum (ER) stress, making it valuable for investigating neurodegenerative diseases, including Alzheimer's and Pick's diseases. Its unique mechanism allows for detailed studies of Tau pathology and potential therapeutic strategies. -
Tau Protein Aggregation Inhibitor
ACI-3024 is a potent, orally active inhibitor of Tau protein aggregation. It effectively reduces the β-sheet content and seeding properties of abnormal Tau proteins associated with various Tauopathies, thereby significantly alleviating Tau-induced neurodegeneration and neuroinflammation in cellular models. ACI-3024 serves as a valuable tool for research into neurodegenerative diseases. -
Polypeptide
Tau Peptide (274-288) is a polypeptide that plays a significant role in neurobiology through its interaction with tau protein. This peptide is widely utilized in research applications focused on protein-protein interactions, functional analyses, and epitope mapping. It serves as a valuable tool in the exploration of tau-related pathologies, aiding in the understanding of neurodegenerative diseases such as Alzheimer's. -
Tau fragment
Tau Peptide (306-336) (Repeat 3 Domain) targets the Tau protein, specifically the repeat domain that plays a crucial role in microtubule stabilization. This peptide fragment facilitates studies on Tau's involvement in neurodegenerative diseases, particularly Alzheimer's disease, by helping to elucidate the mechanisms of Tau aggregation and function. It serves as a valuable tool for researchers investigating Tau-related pathology and potential therapeutic interventions. -
TAU Inhibitor
TAU-IN-3 is an orally active inhibitor of tau protein. This compound effectively inhibits the expression of the MAPT exon 10 DDPAC mutant gene in HeLa cells, demonstrating an IC50 of 0.6 µM. It reduces the 4-repeat/3-repeat MAPT mRNA ratio in cells with wild-type or DDPAC minigenes and inhibits the insertion of endogenous MAPT exon 10, subsequently decreasing the production of 4-repeat tau protein. TAU-IN-3 also modulates tau splicing in htau mice, yielding improvements in associated behavioral phenotypes, making it a valuable reagent for studies on neurodegenerative diseases. -
Tau Fibrilization Inhibitor
Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2 is a N-amino peptide that selectively inhibits tau protein fibrilization. This compound effectively prevents the cellular seeding of endogenous tau by binding to both monomeric and fibrillar forms of extracellular tau. Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2 is valuable for research in neurodegenerative diseases, including Alzheimer's disease, providing insight into tau pathology and potential therapeutic interventions. -
Tau Inhibitor
TAU-IN-6 is a selective inhibitor of Tau protein misfolding and aggregation. It effectively inhibits the formation of stress granules comprising Tau and TIA1, making it a valuable tool in studying Tau pathology. This compound is particularly relevant for research related to Alzheimer's disease and other tauopathies. -
Aggregated Tau Protein Binder
JNJ-64326067 is an aggregated tau protein binder with a Ki of 2.4 nM, demonstrating significant blood-brain barrier permeability. This compound selectively targets aggregated tau protein while exhibiting no binding affinity for aggregated β-amyloid or off-target interactions with various receptors, ion channels, transporters, kinases, and monoamine oxidases. JNJ-64326067 is a valuable tool for investigating the pathophysiology of Alzheimer's disease and exploring potential therapeutic strategies. -
Salicylate Lithium Salt
Lithium salicylate is a lithium salt of salicylic acid that primarily targets tau phosphorylation. It exhibits potential therapeutic effects by reducing tau hyperphosphorylation, thereby alleviating related pathologies in models of Alzheimer's disease. This compound is valuable for research into Alzheimer's mechanisms and potential treatments. -
TTBK1/TTBK2 Inhibitor
TTBK1/2-IN-2 is a selective inhibitor of Tau tubulin kinase 1 (TTBK1) and TTBK2, exhibiting IC50 values of 384 nM and 175 nM, respectively. This compound has been shown to significantly influence ciliogenesis in human induced pluripotent stem cells (iPSCs), making it a valuable tool for studying the roles of TTBK1 and TTBK2 in cellular processes and related pathologies. Its potent inhibitory activity positions TTBK1/2-IN-2 as an important reagent for research in neurodegenerative diseases and cilia-related disorders. -
Tau fragment
Tau Peptide (379-408) is a specific fragment of the tau protein, which is integral to neurodegenerative research, particularly in the study of tauopathies. This peptide serves as a crucial tool for understanding tau aggregation, neurofibrillary tangles formation, and synaptic dysfunction. Its applications include investigating mechanisms of tau-related pathologies and evaluating therapeutic interventions targeting tau misfolding and toxicity. -
Tau Peptide
Acetyl-PHF5 amide is a tau peptide that demonstrates amyloidogenic properties, facilitating the polymerization into filamentous structures. This compound is valuable for research into tau-related pathologies, such as Alzheimer's disease, and is used to study the mechanisms of tau aggregation and neurodegeneration. Its ability to replicate key features of tau protein behavior makes it an essential tool for investigating therapeutic strategies targeting tauopathies. -
Tau-aggregation Inhibitor
Tau-aggregation-IN-3 is a potent inhibitor of Tau protein aggregation, demonstrating an EC50 value of 4.816 μM in cell-based assays. This compound is valuable for research into neurodegenerative diseases, particularly Alzheimer's disease, where Tau aggregation plays a critical role in pathogenesis. Its ability to inhibit Tau aggregation makes it a useful tool for investigating therapeutic strategies aimed at Tau-related mechanisms. -
Tau Aggregate Ligand
Tau ligand-2 is a selective tau aggregate ligand with a Ki value of 0.99 nM. Radiolabeled with fluorine-18, this compound serves as a positron emission tomography (PET) tracer, enabling the visualization of tau pathology. Tau ligand-2 is particularly relevant for research on Alzheimer's disease and other tauopathies, aiding in the understanding of neurodegenerative processes. -
TAU Inhibitor
TAU-IN-2 is a selective TAU inhibitor that demonstrates an EC50 value of 7.7 nM. This compound is primarily utilized in the investigation of neurodegenerative diseases, making it a valuable tool for researchers studying the role of TAU protein aggregation in conditions such as Alzheimer’s disease. Its potent inhibitory action allows for detailed exploration of TAU-related pathways and potential therapeutic interventions. -
Tau Protein Inhibitor
LDN-193665 is a potent inhibitor of Tau kinases, demonstrating significant tauopathy-modifying activity. This compound effectively reduces Tau phosphorylation and decreases Sarkosyl-insoluble Tau levels in preclinical models. Additionally, LDN-193665 has been shown to enhance cognitive function, restoring memory in animal studies and highlighting its potential application in researching tauopathies. -
Anti-MAPT Antibody
Moponetug is a humanized IgG1κ antibody specifically targeting microtubule-associated protein tau (MAPT). This antibody plays a crucial role in studying tau-related neurodegenerative diseases, including Alzheimer's disease and other tauopathies. It is designed for applications such as immunohistochemistry, western blotting, and flow cytometry, facilitating the investigation of tau protein dynamics and pathology in various research contexts. -
TTBK1/TTBK2 Inhibitor
TTBK1/2-IN-1 is a selective inhibitor of Tau tubulin kinases TTBK1 and TTBK2, demonstrating IC50 values of 816 nM and 384 nM, respectively. This compound effectively interferes with tau phosphorylation, making it a valuable tool in research focused on tauopathies and neurodegenerative diseases. Its application can aid in understanding the role of TTBK1 and TTBK2 in cellular processes and serve as a basis for the development of therapeutics targeting tau-related pathologies. -
TTBK1 Inhibitor
TTBK1-IN-3 is a selective inhibitor of TTBK1, exhibiting a biochemical IC₅₀ of 18 nM and a cellular IC₅₀ of 259 nM. This compound is valuable for investigating the role of TTBK1 in Alzheimer's disease research. Its potency allows for detailed studies on the enzymatic pathways involved in neurodegenerative processes. -
Tau fragment
Tau Peptide (1-16) (human) is a fragment of the Tau protein, primarily targeting Tau-mediated pathways involved in neurodegenerative diseases. This peptide is crucial for studying the role of Tau in processes such as microtubule stabilization and neurofibrillary tangle formation. It serves as an important tool for research applications focused on Alzheimer's disease and other tauopathies. -
Tau/pre-miRNA-146a Inhibitor
MG-1102 is a first-in-class dual binder targeting both monomeric tau and pre-miRNA-146a. It exhibits specific inhibition of pre-miRNA-146a, with IC50 values of 0.21 mM for double-labeled and 0.36 mM for mono-labeled forms. Additionally, MG-1102 shows a binding affinity for tau monomers, characterized by a Kd of 3.21 mM as determined by surface plasmon resonance (SPR). This compound serves as a potential multi-target-directed ligand (MTDL) for research applications related to Alzheimer’s disease. -
Tau fragment
Tau Peptide (74-102) (Exon 3/Insert 2 Domain) is a specific fragment of the tau protein that plays a crucial role in stabilizing microtubules in neurons. This peptide is instrumental in research focusing on tauopathies, including Alzheimer’s disease, where tau aggregation and dysfunction are key pathological features. By utilizing this peptide, researchers can investigate tau-related mechanisms and develop potential therapeutic strategies for neurodegenerative disorders. -
Tau Protein Aggregation Inhibitor
Hydromethylthionine dihydrobromide is a potent inhibitor of tau protein aggregation. By interacting with tau proteins, it effectively prevents the formation of neurotoxic aggregates, thereby reducing neurodegeneration. This compound is valuable for research involving Alzheimer's disease and other tau-related disorders, providing insights into the mechanisms of neurodegenerative processes. -
TTBK1 Inhibitor
TTBK1-IN-5 is a selective inhibitor of TTBK1, exhibiting an IC₅₀ value of 239 nM. It is designed for studies investigating the role of TTBK1 in neurodegenerative disorders, particularly Alzheimer's disease. This compound facilitates research aimed at understanding TTBK1's biological function and its potential as a therapeutic target in Alzheimer's pathology. -
Tau-0N4R Inhibitor
Tau-0N4R-IN-1 is an effective inhibitor of tau 0N4R oligomerization, capable of penetrating the blood-brain barrier. This compound demonstrates significant biological activity by inhibiting tau fibrosis across different isoforms, exhibiting anti-seeding effects on tau in vitro, and dose-dependently reducing α-synuclein oligomerization and inclusions. Additionally, Tau-0N4R-IN-1 is stable in mouse microsomes and has been shown to decrease amyloid-beta plaques in brain tissues from Alzheimer's disease patients, making it a valuable reagent for neurological research and drug development. -
Tau/Amyloid-β Aggregation Inhibitor
TRV-1387 is a benzofurazan compound that functions as an inhibitor of tau and amyloid-β aggregation. It demonstrates significant biological activity in preventing the formation of toxic aggregates associated with neurodegenerative diseases, making it a valuable tool for research in Alzheimer's disease and related pathologies. TRV-1387 can be utilized to study the mechanisms of amyloid-related toxicity and to explore potential therapeutic strategies targeting protein aggregation. -
Tau/Aβ Inhibitor
D-687 is a selective inhibitor of Tau and amyloid-beta (Aβ) aggregation. It has demonstrated the ability to reverse Aβ1–42-induced neurotoxicity in SH-SY5Y neuronal cells, highlighting its significant neuroprotective effects. This compound is valuable for research focused on Alzheimer's disease and related neurodegenerative disorders. -
Tau/Aβ Inhibitor
D-688 is a potent inhibitor of Tau and amyloid-beta (Aβ), demonstrating significant neuroprotective properties. This compound effectively reverses Aβ1–42-induced toxicity in SH-SY5Y neuronal cells, making it a valuable tool for studying neurodegenerative processes. Additionally, D-688 improves the survival rate of Drosophila melanogaster models expressing the human tau protein isoform (2N4R), underscoring its potential in Alzheimer's disease research and related disorders. -
Tau Imaging Ligand
THK-523 is a selective tau imaging ligand that targets tau pathology associated with neurodegenerative disorders, particularly Alzheimer's disease. Demonstrating high affinity and specificity, THK-523 is effective as an in vivo radiotracer, facilitating the imaging of tau aggregates. Its applications extend to research in tau-related pathologies, aiding in the understanding of tau's role in neurodegeneration and the development of potential therapeutic strategies. -
Aβ40/tau Aggregation Inhibitor
Tau/Aβ40 aggregation-IN-1 is a potent inhibitor of tau and Aβ40 aggregation, exhibiting IC50 values of 1.8 μM and 1.3 μM, respectively. This compound is of significant interest in Alzheimer's disease research, as it targets the pathological aggregation of tau protein and amyloid-beta peptides. Its effectiveness in modulating these protein interactions makes it a valuable tool for studying neurodegenerative mechanisms and potential therapeutic interventions. -
MAO-B Inhibitor
MAO-B-IN-50 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.06 μM. This compound is effective in inhibiting the aggregation of amyloid-beta (Aβ40/42) and Tau proteins, with overall IC50 values near 1 μM. Additionally, MAO-B-IN-50 shows potent selective inhibition of acetylcholinesterase (AChE) with an IC50 of 1.78 μM. It is suitable for use in research related to Alzheimer's disease. -
Aβ Fibrillogenic Inhibitor
Acetyl-Tau Peptide (273-284) amide is an acetylated fragment of the Tau protein that acts as an inhibitor of Aβ fibrillogenesis. It effectively reduces the aggregation of Ac-Aβ(25–35)-NH2, facilitating studies on the interplay between Aβ and Tau proteins. This peptide serves as a valuable experimental tool for investigating the mechanisms underlying Alzheimer's disease and related neurodegenerative conditions. -
PHF6/Tau Disrupter
Cl-NQTrp is a potent disrupter of preformed fibrillar aggregates associated with Tau-derived PHF6 (VQIVYK) peptides and full-length tau protein. This compound exhibits substantial activity in modulating tau aggregation, making it a valuable tool for research focused on tauopathies and Alzheimer's disease. Its role in disrupting tau pathology positions Cl-NQTrp as a key reagent for studies investigating therapeutic strategies against neurodegenerative disorders characterized by abnormal tau accumulation. -
Amyloid-Beta and Tau Inhibitor
Aβ/tau aggregation-IN-1 is a selective inhibitor of amyloid-beta (Aβ1-42) β-sheet formation and tau protein aggregation. With KD values of 160 μM for Aβ1-42 and 337 μM for tau, this compound demonstrates significant potential in research related to neurodegenerative disorders such as Alzheimer's disease. Its ability to cross the blood-brain barrier further supports its use in studies aimed at understanding the pathophysiology of amyloid and tau accumulation in the central nervous system. -
Aβ/tau Protein Aggregation Inhibitor
DN5355 is a small molecule inhibitor of amyloid β protein (Aβ) and hyperphosphorylated tau protein aggregation. It effectively inhibits the formation of Aβ and tau fibrils while also promoting the disaggregation of pre-formed aggregates. This compound is valuable for research applications focused on Alzheimer's disease and the underlying mechanisms of protein aggregation associated with neurodegeneration. -
Anti-amyloid Drug
Aβ/tau aggregation-IN-3 is a potent inhibitor of amyloid protein aggregation, demonstrating an IC50 of 0.85 μM in the Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. This compound exhibits significant anti-amyloid activity, making it a valuable tool for research into Alzheimer’s disease and other amyloid-related disorders. Its mechanism of action positions it as a promising candidate for investigations focused on therapeutic strategies aimed at reducing amyloid plaque formation. -
Neuroprotective Agent
(-)-Clausenamide is a neuroprotective agent isolated from the leaves of Clausena lansium (Lour.) Skeels that enhances cognitive function under both normal and pathological conditions. It effectively inhibits β-amyloid (Aβ) toxicity and prevents neurofibrillary tangle formation by blocking tau protein phosphorylation. Additionally, (-)Clausenamide demonstrates significant neuroprotective activity against the Aβ25-35 peptide. This compound is valuable for research applications related to Alzheimer's disease (AD).
-
tau Peptide
AADvac 1 is an active tau peptide vaccine targeting tau pathology in Alzheimer's disease research. This vaccine consists of the regulatory peptide 294KDNIKHVPGGGS305, which promotes tau oligomerization, conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide as an adjuvant. AADvac 1 has potential applications in studying immune responses to tau aggregates, contributing to the understanding of Alzheimer's disease mechanisms and therapeutic strategies.
